Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response

被引:25
作者
Legros, Laurence [1 ,2 ]
Rousselot, Philippe [3 ]
Giraudier, Stephane [4 ]
Tulliez, Michel [4 ]
Huguet, Francoise [5 ]
Nicolini, Franck-Emmanuel [6 ]
Mahon, Francois-Xavier [7 ,8 ]
机构
[1] Hop Archet 1, Serv Hematol Clin, F-06202 Nice 2, France
[2] Inst Dev Biol & Canc Res, Ctr Natl Rech Sci, Unite Mixte Rech 6543, Nice, France
[3] Univ Versailles, Ctr Hosp Versailles, Le Chesnay, France
[4] Hop Henri Mondor, F-94010 Creteil, France
[5] Hop Purpan, Toulouse, France
[6] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France
[7] Univ Bordeaux Segalen, Inserm 1035, Inst Bergonie, Ctr Hosp Univ Bordeaux,Hematol Lab, Bordeaux, France
[8] Univ Bordeaux Segalen, Inserm 1035, Inst Bergonie, Ctr Hosp Univ Bordeaux,Serv Malad Sang, Bordeaux, France
关键词
D O I
10.1182/blood-2012-02-408229
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1959 / 1960
页数:4
相关论文
共 1 条
[1]   Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial [J].
Mahon, Francois-Xavier ;
Rea, Delphine ;
Guilhot, Joelle ;
Guilhot, Francois ;
Huguet, Francoise ;
Nicolini, Franck ;
Legros, Laurence ;
Charbonnier, Aude ;
Guerci, Agnes ;
Varet, Bruno ;
Etienne, Gabriel ;
Reiffers, Josy ;
Rousselot, Philippe .
LANCET ONCOLOGY, 2010, 11 (11) :1029-1035